Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT00096447 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

NIH

Sponsor class

Conditions

Recurrent Endometrial Carcinoma

Interventions

DRUG: lapatinib ditosylate

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]